BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22333588)

  • 1. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.
    Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Menendez OJ; Bosch-Barrera J; Martin-Castillo B; Joven J; Menendez JA
    Cell Cycle; 2012 Mar; 11(5):865-70. PubMed ID: 22333588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
    Cell Cycle; 2009 Jan; 8(1):88-96. PubMed ID: 19106626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
    Whitaker-Menezes D; Martinez-Outschoorn UE; Flomenberg N; Birbe RC; Witkiewicz AK; Howell A; Pavlides S; Tsirigos A; Ertel A; Pestell RG; Broda P; Minetti C; Lisanti MP; Sotgia F
    Cell Cycle; 2011 Dec; 10(23):4047-64. PubMed ID: 22134189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
    Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
    Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
    Menendez JA; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Vellon L; Vazquez-Martin A
    Aging (Albany NY); 2011 Nov; 3(11):1063-77. PubMed ID: 22170748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Lopez-Bonet E; Menendez JA
    Oncol Rep; 2011 Jan; 25(1):135-40. PubMed ID: 21109968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells.
    Damjanović A; Matić IZ; Ðorđić M; Ðurović MN; Nikolić S; Roki K; Milovanović Z; Antić-Stanković J; Džodić R; Damjanović S; Kanjer K; Abu Rabi Z; Juranić Z
    Pathol Oncol Res; 2015 Jul; 21(3):605-12. PubMed ID: 25351941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
    Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
    Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
    Alimova IN; Liu B; Fan Z; Edgerton SM; Dillon T; Lind SE; Thor AD
    Cell Cycle; 2009 Mar; 8(6):909-15. PubMed ID: 19221498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PYK2 promotes HER2-positive breast cancer invasion.
    Al-Juboori SI; Vadakekolathu J; Idri S; Wagner S; Zafeiris D; Pearson JR; Almshayakhchi R; Caraglia M; Desiderio V; Miles AK; Boocock DJ; Ball GR; Regad T
    J Exp Clin Cancer Res; 2019 May; 38(1):210. PubMed ID: 31118051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands.
    Komov L; Kadosh DM; Barnea E; Milner E; Hendler A; Admon A
    Proteomics; 2018 Jun; 18(12):e1700248. PubMed ID: 29707912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
    Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells.
    Amaral I; Silva C; Correia-Branco A; Martel F
    Biomed Pharmacother; 2018 Jun; 102():94-101. PubMed ID: 29550639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines.
    Goodrich KH; Alvarez X; Holcombe RF
    Cancer; 1993 Jul; 72(1):225-30. PubMed ID: 8508411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors.
    Solana R; Romero J; Alonso C; Peña J
    Invasion Metastasis; 1992; 12(3-4):210-7. PubMed ID: 1294532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.